알부민 시장 규모는 2023년 66억 9,000만 달러로 평가되며, 2024년 70억 8,000만 달러에서 2032년 112억 1,000만 달러로 성장하여 예측 기간(2025-2032년) 동안 5.9%의 CAGR로 성장할 것으로 예상됩니다.
알부민 세계 시장은 혈액량 증가, 간 질환 치료, 화상 관리와 같은 중요한 의료 용도로 인해 큰 성장이 예상됩니다. 삼투압 유지 및 필수 물질 수송과 같은 알부민의 주요 기능은 알부민의 치료 가능성을 높이고 있습니다. 성장 촉진요인으로는 생명을 위협하는 질병의 유병률 증가, 외과 수술의 증가(2022년 전 세계 수술 건수 3억 1,000만 건), 비치료적 용도의 증가 등을 들 수 있으며, Grifols의 간경변증에 대한 알부틴 평가, Shilpa Biologicals의 친환경 재조합 인간 알부민과 같은 혁신적인 발전은 보다 효과적이고 지속가능한 제품으로의 전환을 시사하고 있습니다. 알부메딕스와 바르네바의 백신 제제 개선을 위한 협력은 헬스케어 솔루션을 발전시키고 필수 치료에 대한 전 세계인의 접근성을 향상시키기 위한 업계의 노력을 보여줍니다.
Albumin Market size was valued at USD 6.69 billion in 2023 and is poised to grow from USD 7.08 billion in 2024 to USD 11.21 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).
The global albumin market is poised for significant growth due to its critical medical applications in increasing blood volume, treating liver diseases, and managing burn injuries. Key functions of albumin, such as maintaining osmotic pressure and transporting essential substances, enhance its therapeutic potential. Driving factors include the rising prevalence of life-threatening diseases, an increase in surgical procedures-310 million surgeries were performed globally in 2022-and an uptick in non-therapeutic uses. Innovative advancements, like Grifols' evaluation of Albutein for cirrhosis, and Shilpa Biologicals' environmentally friendly recombinant Human Albumin, signal a shift towards more effective and sustainable products. Collaborations, like that of Albumedix with Valneva to improve vaccine formulations, represent the industry's commitment to advancing healthcare solutions and boosting global access to essential treatments.
Top-down and bottom-up approaches were used to estimate and validate the size of the Albumin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Albumin Market Segments Analysis
Global Albumin Market is segmented by Type, Application, Sales Channel, End-User and region. Based on Type, the market is segmented into Human Serum Albumin, Bovine Serum Albumin and Recombinant Albumin. Based on Application, the market is segmented into Therapeutics, Drug Formulation and Vaccines, Component of Media and Other Applications. Based on Sales Channel, the market is segmented into Business-To-Consumer (B2C) and Business-To-Business (B2B). Based on End-User, the market is segmented into Hospitals and Clinics, Pharmaceutical and Biotechnology Companies and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Albumin Market
The albumin market is driven by several key factors, notably the rising demand for albumin in regenerative medicine, vaccine stabilization, and drug formulations. Its significance in contemporary biopharmaceuticals is highlighted by its applications in plasma expansion, drug delivery systems, and nanomedicine. Additionally, the increasing prevalence of chronic diseases, including conditions such as hypovolemia and liver disorders, is prompting pharmaceutical companies to innovate and develop new therapeutic drugs. This growing patient population necessitates advanced treatments, further stimulating the demand for albumin and enhancing its role as a crucial component in various medical applications and drug formulations.
Restraints in the Albumin Market
The albumin market faces significant challenges due to the intricate and costly production processes, particularly for recombinant albumin. The extensive reliance on plasma collection results in complexities surrounding purification and quality control for plasma-derived albumin. Additionally, the operational costs are heightened by fluctuations in plasma supply, stringent regulatory approval processes, and the necessity for cold-chain logistics. These factors collectively impede accessibility and affordability, particularly in developing regions, ultimately acting as major restraints on the albumin market's growth and expansion potential, affecting both manufacturers and end-users alike.
Market Trends of the Albumin Market
The albumin market is experiencing a notable shift towards sustainable production methods, with a growing emphasis on recombinant albumin. Concerns surrounding plasma sourcing, potential pathogen transmission, and supply chain vulnerabilities are driving companies to invest in genetic engineering technologies. This transition is yielding innovative alternatives, including plant-based and yeast-expressed recombinant albumin, which promise enhanced safety and environmental sustainability. As the industry pivots away from traditional plasma-derived products, these advancements not only address contamination risks but also offer cost-effective solutions that appeal to both manufacturers and consumers. This trend underscores a broader commitment to safety and sustainability in biopharmaceutical manufacturing.